Northwest Biotherapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Linda F. Powers
- Full Time Employees
- 105
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4800 Montgomery Lane Bethesda MD United States of America 20814
- IPO Date
- Dec 14, 2001
- CIK
- 0001072379
- Website
- nwbio.com
- Similar Companies
- Business
- Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company that develops personalized immune therapies for solid tumor cancers using its proprietary DCVax platform technology, which activates a patient's own dendritic cells to mobilize the immune system against tumors; the platform enables production of individualized vaccines without the toxicities associated with chemotherapy. The company's lead candidate, DCVax-L, targets glioblastoma multiforme (GBM), the most aggressive form of primary brain cancer, following completion of a 331-patient Phase III trial with results published in JAMA Oncology; DCVax-Direct addresses inoperable solid tumors after a 40-patient Phase I trial, with Phase II trials planned; DCVax-Prostate has advanced through Phase II for late-stage prostate cancer and received clearance for Phase III; additional applications include a Phase I/II trial with the University of Pennsylvania for advanced ovarian cancer. Founded in 1996 and headquartered in Bethesda, Maryland, the company operates GMP manufacturing facilities in the UK, including Sawston and previously London, with clinical trials conducted across the US, Europe, and other regions targeting patients with GBM, inoperable tumors, prostate cancer, and ovarian cancer. Recent developments include the October 2025 closing of its acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary to integrate technologies, intellectual property from NWBio, Advent, and Flaskworks, streamline supply chains, close the London GMP facility, reallocate resources to Sawston and US capacity expansion, and scale manufacturing for DCVax products; recovery of 19 million NWBio securities previously issued to Advent; a $5 million convertible promissory note financing with YA II PN, Ltd. for Sawston Grade C manufacturing suite construction and operations; ongoing review of its Marketing Authorization Application for DCVax-L by the UK MHRA, with potential approval by late 2025 or early 2026; and plans for next-generation immunotherapies and pipeline diversification.
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)
Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Passes Below 200-Day Moving Average – Here’s Why
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Northwest Bio: Another Small Filing Delay